GlassScriptPhysician profile
Joshua Seth Nass
NPI 1033607791
$5,619.84
in general payments reported to CMS, 2019-2025
38 companies · $54.00 in 2025
The $54.00 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2021: $674 · 2022: $576 · 2023: $2,290 · 2024: $1,305 · 2025: $54.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,627.20 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.20 | 2022-2024 | |
| Genzyme Corporation | $539.24 | 2019-2023 | |
| Biogen, INC. | $457.37 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $392.23 | 2022-2024 | |
| Genentech USA, INC. | $375.79 | 2019-2025 | Ocrevus, Enspryng, Tnkase |
| Alexion Pharmaceuticals, INC. | $273.13 | 2019-2024 | Soliris, Ultomiris |
| Ucb, INC. | $267.83 | 2022-2024 | Briviact, Rystiggo |
| Celgene Corporation | $262.18 | 2021-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $189.89 | 2022-2024 | Austedo Xr, Austedo, Ajovy |
| Sk Life Science, INC. | $178.23 | 2021-2023 | |
| Argenx US, INC. | $174.83 | 2022-2023 | Vyvgart |
| Lilly USA, LLC | $169.30 | 2023-2024 | Emgality, Amyvid, Reyvow |
| Otsuka America Pharmaceutical, INC. | $140.96 | 2023 | Rexulti, Nuedexta |
| Greenwich Biosciences, INC. | $126.16 | 2021 | |
| Pfizer INC. | $118.06 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $110.27 | 2021 | |
| Jazz Pharmaceuticals INC. | $105.82 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $102.38 | 2023-2024 | Ingrezza, Ongentys |
| Lundbeck LLC | $91.21 | 2023-2024 | Rexulti, Vyepti |
| Tg Therapeutics, INC. | $90.98 | 2023 | |
| Eisai INC. | $68.69 | 2022-2024 | |
| Philips North America LLC | $67.30 | 2024-2025 | (8874) Incourage, Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $64.95 | 2021-2024 | Aimovig, Uplizna |
| Horizon Therapeutics Plc | $58.25 | 2023 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $50.39 | 2022-2024 | Hyqvia |
| Neurelis, INC. | $41.28 | 2023-2024 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $36.84 | 2022 | |
| Tanabe Pharma America, INC. | $36.67 | 2023 | |
| Acadia Pharmaceuticals INC | $34.63 | 2023-2024 | Daybue, Nuplazid |
| Azurity Pharmaceuticals, INC. | $31.87 | 2023-2024 | Horizant, Horizant |
| Kyowa Kirin, INC. | $31.74 | 2023 | Nourianz |
| Merz Pharmaceuticals, LLC | $27.81 | 2024 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $23.22 | 2024 | |
| Impel Pharmaceuticals INC. | $22.74 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $22.18 | 2023 | Onpattro |
| Allergan, INC. | $21.70 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.70 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Nass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.